The company was founded in 2011 in Suzhou Bio-Nano Park with a registered capital of 360 million yuan. It was founded by Dr. Zhang Dawei, who has studied in the United States and served as the chief scientist of Amgen, one of the world's largest biopharmaceutical companies. The company has a research and development department, a registration department, a clinical department, a production department, and a quality department. The department is well-established, the management is scientific, and the team is proficient in cutting-edge new drug development technology at home and abroad, and has rich experience in new drug research and development and project operation management.
The company focuses on the design, R&D and industrialization of a class of small molecule targeted innovative drugs, and aims to serve human health in the field of tumor diseases where there is no effective clinical treatment method and urgent clinical needs. The company’s technological advantage lies in the fact that new drug projects are combined with the most advanced computer-assisted new drug screening technology, drug R&D theory and practical experience to design innovative anti-tumor drug candidates, which have been fully verified in preclinical experiments. Most of the company's new drug projects have unique brain permeability and high druggability, bringing new hopes for drug treatment to patients with tumor brain metastases.
In the field of oncology, the company has a rich product pipeline and a number of invention patents have been authorized. Currently, there are multiple new drug projects in various stages of clinical development, covering large varieties of areas such as lung cancer, breast cancer, and head and neck squamous cell carcinoma.
The company has an entire production, R&D, and office plant in Taizhou China Medical City, Jiangsu Province, and has obtained a drug production license. The plant covers an area of 11,000 square meters. It plans to continue to increase the targeted drug oral solid preparation workshop that meets the cGMP inspection requirements of the US FDA.
In the next two years, the company will make every effort to promote the successive listing of new drug products, and is committed to helping patients with diseases that currently have no effective clinical treatments and urgent clinical needs, benefiting the society, filling the gaps in related treatment fields at home and abroad, and taking root in China. Go to the world and build an internationally competitive new drug technology company.